WASHINGTON — The Food and Drug Administration on Thursday announced the first nine recipients of the Commissioner’s National Priority Review vouchers, a program designed to expedite drug reviews for companies whose products align with the agency’s national health priorities. This initiative aims to streamline the approval process for critical therapies, thereby enhancing patient access to essential medications.
Among the highlighted recipients is EMD Serono, which was noted by President Trump during a White House news conference focused on expanding access to in vitro fertilization. EMD Serono has committed to lowering prices for its existing fertility drugs in exchange for a priority review voucher for Pergoveris, a drug that stimulates egg development and is already approved in 74 countries. This move underscores the interplay between regulatory incentives and market access strategies in the pharmaceutical landscape.
The implications of this announcement extend beyond individual companies, as it signals the FDA’s commitment to prioritizing therapies that address significant health needs. As the program evolves, stakeholders in regulatory, QA/QC, CMC, sourcing, and portfolio management will need to closely monitor how these vouchers impact drug development timelines and market dynamics.
Start your 7-day trial and see what the database can do →
